TD Asset Management Inc Has $176.73 Million Stock Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• TD Asset Management Inc increased its stake in IDEXX Laboratories by 12.2%, holding approximately $176.73 million in shares as of its most recent SEC filing.
• Various institutional investors own 87.84% of IDEXX Laboratories stock, with some recent activity showing incremental increases in stakes from several investors.
• IDEXX Laboratories reported a quarterly earnings per share (EPS) of $3.63, surpassing analysts' expectations of $3.28, and a revenue increase of 10.6% year-over-year.

TD Asset Management Inc boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 12.2% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 329,511 shares of the company's stock after buying an additional 35,798 shares during the period. TD Asset Management Inc owned approximately 0.41% of IDEXX Laboratories worth $176,730,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Red Spruce Capital LLC grew its stake in IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company's stock valued at $912,000 after buying an additional 19 shares during the last quarter. Rise Advisors LLC grew its position in shares of IDEXX Laboratories by 3.9% during the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company's stock worth $301,000 after purchasing an additional 21 shares in the last quarter. Blue Trust Inc. grew its position in shares of IDEXX Laboratories by 14.2% during the 2nd quarter. Blue Trust Inc. now owns 177 shares of the company's stock worth $95,000 after purchasing an additional 22 shares in the last quarter. Sage Mountain Advisors LLC grew its position in shares of IDEXX Laboratories by 3.8% during the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock worth $267,000 after purchasing an additional 23 shares in the last quarter. Finally, Great Lakes Advisors LLC grew its position in shares of IDEXX Laboratories by 0.9% during the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company's stock worth $1,078,000 after purchasing an additional 23 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They set a "buy" rating and a $625.00 target price on the stock. Piper Sandler restated a "neutral" rating and set a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. Stifel Nicolaus set a $640.00 target price on shares of IDEXX Laboratories in a research report on Monday, August 4th. UBS Group began coverage on shares of IDEXX Laboratories in a report on Wednesday, October 1st. They set a "neutral" rating and a $720.00 price target for the company. Finally, Weiss Ratings reaffirmed a "buy (b-)" rating on shares of IDEXX Laboratories in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $656.50.

Insiders Place Their Bets

In other news, EVP Sharon E. Underberg sold 5,450 shares of the firm's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the transaction, the executive vice president owned 6,156 shares of the company's stock, valued at approximately $4,011,249.60. This trade represents a 46.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the firm's stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares of the company's stock, valued at $52,650,885.78. The trade was a 25.99% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 54,057 shares of company stock worth $34,293,468. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $636.91 on Wednesday. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The firm has a market capitalization of $50.96 billion, a P/E ratio of 53.03, a P/E/G ratio of 4.10 and a beta of 1.58. The company's 50 day moving average price is $640.40 and its two-hundred day moving average price is $545.72.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to analysts' expectations of $1.06 billion. During the same quarter in the prior year, the firm earned $2.44 EPS. The business's revenue for the quarter was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.